Antengene Corporation Limited (FRA:722)

Market Cap	299.61M -36.7%
Revenue (ttm)	72.83M +570.1%
Net Income	6.91M
EPS	0.01
Shares Out	n/a
PE Ratio	43.39
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.4240
Previous Close	0.4140
Day's Range	0.4240 - 0.4240
52-Week Range	0.2860 - 0.8500
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 21, 2026

About Antengene Corporation

Antengene Corporation Limited, a clinical-stage APAC biopharmaceutical company, develops novel oncology therapies in Greater China and internationally. The company’s commercialized assets include ATG-010 (selinexor), an oral SINE compound for the treatment of various hematological malignancies and solid tumors comprising relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse large B-cell lymphoma, and multiple myeloma (MM) in adult patients. Its late-stage products candidates comprise ATG-008 (onatasertib), an mTOR inhibitor f...

• Industry: Pharmaceutical Preparations
• Founded: 2017
• Employees: 129
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 722

Financial Performance

In 2025, Antengene Corporation's revenue was 105.34 million, an increase of 14.56% compared to the previous year's 91.95 million. Losses were -239.13 million, -25.10% less than in 2024.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 26, 2026

Data Sources Report a data error